EYPT - EyePoint Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.03
-0.12 (-5.58%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.15
Open2.17
Bid2.03 x 900
Ask2.25 x 1200
Day's Range2.03 - 2.24
52 Week Range0.93 - 3.94
Volume332,204
Avg. Volume599,410
Market Cap192.557M
Beta (3Y Monthly)-0.46
PE Ratio (TTM)N/A
EPS (TTM)-1.46
Earnings DateFeb 5, 2019 - Feb 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.17
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU™ by the Center for Medicare and Medicaid Services (CMS)  

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code through the Healthcare Common Procedure Coding System (HCPCS) for DEXYCU™ (dexamethasone intraocular suspension) 9%. “The issuance of a specific and permanent J-code for DEXYCU is another key milestone for the Company that allows for a convenient and simplified reimbursement process that is familiar to administering physicians and the greater insurance community,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. The code, J1095, will become effective on January 1, 2019, and will replace the previously issued C-code for DEXYCU (C9034) that became effective on October 1, 2018.

  • GlobeNewswire8 days ago

    EyePoint Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference

    WATERTOWN, Mass., Nov. 06, 2018 -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative.

  • EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Lags Revenue Estimates
    Zacks8 days ago

    EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Lags Revenue Estimates

    EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -46.15% and -30.57%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga8 days ago

    The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 5) Allakos Inc (NASDAQ: ALLK ) Allogene Therapeutics Inc ...

  • Associated Press8 days ago

    EyePoint Pharmaceuticals: Fiscal 1Q Earnings Snapshot

    On a per-share basis, the Watertown, Massachusetts-based company said it had a loss of 44 cents. Losses, adjusted for non-recurring costs, were 19 cents per share. The drug delivery technology company ...

  • GlobeNewswire8 days ago

    EyePoint Pharmaceuticals Reports Fiscal First Quarter 2019 Financial Results and Highlights Recent Clinical and Operational Developments

    -YUTIQ™ approved by U.S. FDA; anticipated launch in calendar 1Q19- -Exclusive license granted to Ocumension Therapeutics to develop and commercialize EyePoint’s three-year.

  • GlobeNewswire9 days ago

    EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert™ Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension Therapeutics today announced an exclusive license agreement for the development and commercialization of EyePoint’s three-year micro insert using the Durasert™ technology for chronic, non-infectious posterior segment uveitis in the greater China territory, which is comprised of China, Hong Kong, Macau and Taiwan. EyePoint received approval for this product by the U. S. Food and Drug Administration (FDA) on October 12, 2018, and will be marketing it in the U.S. under the brand name YUTIQ™.

  • GlobeNewswire15 days ago

    EyePoint Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results Release Date and Conference Call Information

    WATERTOWN, Mass., Oct. 30, 2018 -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative.

  • GlobeNewswire15 days ago

    EyePoint Pharmaceuticals Appoints John Landis, Ph.D., M.S., to Board of Directors

    EyePoint Pharmaceuticals (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the appointment of John Landis, Ph.D., M.S., to the Company’s Board of Directors. Dr. Landis, a veteran pharmaceutical sciences executive, has led development functions including pharmacy, analytical chemistry, process chemistry, biotechnology, devices, clinical supplies, and quality assurance.

  • GlobeNewswire16 days ago

    EyePoint Pharmaceuticals Presents Positive YUTIQ™ 24-month Follow-up Data at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting

    EyePoint Pharmaceuticals (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of 24-month efficacy and safety data supporting the Company's YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. “Decreasing or eliminating uveitis flares is a critical factor in managing non-infectious posterior-uveitis as recurrences of attacks can lead to blindness if not properly treated.

  • GlobeNewswire27 days ago

    EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ™ to be Presented at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting

    - Five oral abstracts to be presented at annual meeting and subspecialty days –-24-month follow up YUTIQ data to be highlighted at a breakthrough presentation- WATERTOWN,.

  • EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq
    Zacks28 days ago

    EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq

    EyePoint (EYPT) gains an FDA approval for its eye therapy Yutiq to help cure chronic non-infectious uveitis affecting the posterior segment of the eye.

  • EyePoint Pharmaceuticals (EYPT) Catches Eye: Stock Jumps 6.8%
    Zacks29 days ago

    EyePoint Pharmaceuticals (EYPT) Catches Eye: Stock Jumps 6.8%

    EyePoint Pharmaceuticals (EYPT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • Market Exclusivelast month

    Stock Market News Daily Roundup October 15

    Netflix, PayPal, IBM, Others Reporting This Week Many key companies are set to report earnings this week. Bank of America has reported its quarterly results today while Morgan Stanley, Goldman Sachs, Netflix, United Airlines, Johnson & Johnson, BlackRock, and IBM will report earnings on Tuesday. On Wednesday, earnings will be released by United Rentals and […] The post Stock Market News Daily Roundup October 15 appeared first on Market Exclusive.

  • MarketWatchlast month

    EyePoint Pharma shares jump on FDA approval of Yutiq implant

    EyePoint Pharmaceuticals Inc. shares soared 8% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has approved its Yutiq implant for the treatment of uveitis, a leading cause of blindness. Yutiq is a micro-insert that is designed to release fluocinolone acetonide over a three-year period and that can be administered in a doctor's office. :Chronic non-infectious uveitis affecting the posterior segment of the eye is the third leading cause of blindness in the U.S.," Chief Executive Nancy Lurker said in a statement. The company is expecting to launch the product in the first quarter of 2019. EyePoint shares have gained 199% in 2018, while the S&P 500 has gained 3.5%.

  • GlobeNewswirelast month

    EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced today that the U. S. Food and Drug Administration (FDA) has approved YUTIQ™ (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ utilizes the Company’s Durasert™ drug delivery technology and is a non-bioerodible intravitreal micro-insert in a drug delivery system containing 0.18 mg fluocinolone acetonide, designed to release consistently over 36 months.

  • Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options
    Zackslast month

    Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options

    Investors need to pay close attention to EyePoint Pharmaceuticals (EYPT) stock based on the movements in the options market lately.

  • GlobeNewswirelast month

    EyePoint Pharmaceuticals Announces Proceeds of $28.9 Million from Exercised Warrants

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company has received proceeds of $28.9 million from the exercise of warrants by EW Healthcare Partners, Rosalind Advisors, Inc., and another accredited investor (Second Tranche Investors). “We are pleased to receive the continued support of  EW Healthcare Partners,  Rosalind Advisors and our other investors, for our innovative pipeline of ocular disease products,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals.

  • GuruFocus.com2 months ago

    US Stocks Lower on Wednesday

    EyePoint Pharmaceuticals down more than 3% after reporting results

  • EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates
    Zacks2 months ago

    EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates

    EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -111.11% and 6.72%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    EyePoint Pharmaceuticals: Fiscal 4Q Earnings Snapshot

    The Watertown, Massachusetts-based company said it had a loss of 62 cents per share. Losses, adjusted for non-recurring costs, were 19 cents per share. The drug delivery technology company posted revenue ...

  • GlobeNewswire2 months ago

    EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress

    -Substantial progress made in the Company’ s accelerated transformation into a commercial entity. -YUTIQ™ PDUFA date of November 5, 2018. -Commercial preparations underway for launch of DEXYCU™ in the ...

  • GlobeNewswire2 months ago

    EyePoint Pharmaceuticals Elects Göran Ando, M.D. as Next Chairman of Board of Directors

    EyePoint Pharmaceuticals (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company’s Board of Directors has elected Göran Ando, M.D., as its next Chairman of the Board. As part of this transition, David J. Mazzo, Ph.D., will step-down as Non-Executive Chairman, but will remain on the Board and will continue to serve as Chair of the Compensation Committee. “We are pleased to have Dr. Ando serve as our Chairman of the Board as we continue our transition into a commercial-stage specialty pharmaceuticals company,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals.

  • ACCESSWIRE2 months ago

    Healthcare Stocks Take Center Stage In September

    CORAL GABLES, FL / ACCESSWIRE / September 6, 2018 / The healthcare industry has become one of the fastest growing industries in the world. The growing advancements in the industry are steadily contributing towards its market growth. According to the findings of the latest study, expansion in the current market, new product development, and improving operational effectiveness are the top three priorities for the healthcare companies over the next six months.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Novartis Divestment, Eyepoint's Drug Gets Coverage, Spectrum's Robust Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Sept. 5) Aptinyx Inc (NASDAQ: APTX ) Avanos Medical Inc (NYSE: AVNS ...